Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients
Christoph Höner zu Siederdissen(Medizinische Hochschule Hannover), Markus Cornberg(Medizinische Hochschule Hannover), Sandrine Stepien(The University of Sydney), Christian Trépo(Université Claude Bernard Lyon 1), Paul Gineste(Abivax (France)), Josianne Nitcheu(Abivax (France)), Gerardo Guillén(Hunan City University), Heiner Wedemeyer(Medizinische Hochschule Hannover), Pisit Tangkijvanich(Chulalongkorn University), Aric J. Hui(Alice Ho Miu Ling Nethersole Hospital), Wattana Sukeepaisarnjaroen(Khon Kaen University), Michael P. Manns(Medizinische Hochschule Hannover), Wei Su(University of Hawaiʻi at Mānoa), Sandrine Crabé(Abivax (France))
Cited by 58
Related Papers
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis
|Journal of Hepatology|1999|2.9k
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877